PORTLAND, Oregon and PUNE, India, July 17, 2018 /PRNewswire/ --
According to a new report published by Allied Market Research, titled, "Migraine Drugs Market by Type, Route of Administration, and Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2018-2025", the market was valued at $1,713 million in 2017, and is expected to reach $2,190 million by 2025, growing at a CAGR of 3.1% from 2018 to 2025. North America is anticipated to be the highest revenue contributor throughout the forecast period.
Increase in prevalence of migraine, rapid rise in female population, and surge in awareness among patients for migraine treatment & prevention drive the growth of the global migraine drugs market. However, side effects of migraine drugs are expected to limit the market growth. Conversely, emerging new therapies/drugs for migraine treatment and growth opportunities in the emerging nations are expected to present opportunities for the market growth during the forecast period.
By type, abortive medicines accounted for more than three-fourths share of the global migraine drugs market in 2017. Furthermore, by route of administration, the oral segment is anticipated to grow at the highest rate of 3.4% during the forecast period.
KEY FINDINGS OF THE STUDY
North America occupied two-fifths share of the global migraine drugs market.
Oral is anticipated to grow with the highest CAGR throughout the forecast period.
Europe is anticipated to occupy more than one-fourth market share of the global migraine drugs market by 2025.
Asia-Pacific is anticipated to grow at the highest rate during the analysis period, followed by LAMEA.
North America was the leading revenue contributor to the global market in 2017, owing to surge in demand for better healthcare along with effective government reforms for awareness towards migraine & its prevention. However, Asia-Pacific is expected to grow at the highest CAGR of 4.4% from 2018 to 2025, due to improvements in healthcare infrastructure and rise in demand for better healthcare facilities.
The report provides an extensive competitive analysis and profiles of the key market players such as Abbott Laboratories, Allergan Plc., AstraZeneca, Eisai Co., Ltd., Endo International Plc., GlaxoSmithKline Plc., Impax Laboratories, Johnson & Johnson, Merck & Co., and Pfizer Inc. The other players in the value chain (not included in the report) include Novartis International AG, Teva Pharmaceutical Industries Limited, and Sanofi SA.
Knowledge tree is a cloud-based intelligence platform that offers more than 2,000 selective, off-the-shelf reports on niche markets to enable our clients gain deep insights on the latest trends, dynamic technologies, and emerging application areas.
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.
Contact: Shriram Dighe 5933 NE Win Sivers Drive #205, Portland, OR 97220 United States Toll Free: +1-800-792-5285 UK: +44-845-528-1300 Hong Kong: +852-301-84916 India (Pune): +91-20-66346060 Fax: +1⟨855⟩550-5975 email@example.com